A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
Public ClinicalTrials.gov record NCT03809663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined With Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).
Study identification
- NCT ID
- NCT03809663
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 251 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2019 (Actual)
- Primary completion
- May 12, 2020 (Actual)
- Completion
- Dec 22, 2020 (Actual)
- Last update posted
- Mar 10, 2022
2019 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| First OC Dermatology | Fountain Valley | California | 92708 | — |
| Clinical Science Institute | Santa Monica | California | 90404 | — |
| Hamilton Research, LLC | Alpharetta | Georgia | 30022 | — |
| Southern Illinois University School of Medicine | Springfield | Illinois | 62702 | — |
| Dundee Dermatology | West Dundee | Illinois | 60118 | — |
| DS Research | Clarksville | Indiana | 47129 | — |
| Epiphany Dermatology of Kansas, LLC | Overland Park | Kansas | 66215 | — |
| Skin Sciences Pllc | Louisville | Kentucky | 40217 | — |
| Scott Health Services LLC | Louisville | Kentucky | 40241 | — |
| Clarkston Skin Research | Clarkston | Michigan | 48346 | — |
| J Woodson Dermatology and Associates | Henderson | Nevada | 89052 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| DermResearch Center of New York Inc | Stony Brook | New York | 11790 | — |
| Tennessee Clinical Research Center | Nashville | Tennessee | 37215 | — |
| Modern Research Associates | Dallas | Texas | 75231 | — |
| Premier Clinical Research | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03809663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2022 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03809663 live on ClinicalTrials.gov.